Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has lifted its price ...
Neutral
1.0